Evaluation of aquaporin-4 antibody assays

Clinical and Experimental Neuroimmunology

Volumn 5, Issue 3, 2014, Pages 290-303

  Waters, Patrick J ^a   Pittock, Sean J ^b   Bennett, Jeffrey L ^c   Jarius, Sven ^d   Weinshenker, Brian G ^b   Wingerchuk, Dean M ^e  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b Mayo Clinic College of Medicine   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e MAYO CLINIC   (United States)

Author keywords

antibody; aquaporin 4 immunoglobulin G; multiple sclerosis; neuromyelitis optica; neuromyelitis optica immunoglobulin G

Indexed keywords

AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G;

ANTIBODY DETECTION; BLOOD LEVEL; BLOOD SAMPLING; CELL ASSAY; CEREBROSPINAL FLUID ANALYSIS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE IMMUNOPRECIPITATION ASSAY; GENETIC TRANSFECTION; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; RADIOIMMUNOPRECIPITATION; RELAPSE; REVIEW;

EID: 84905846118     PISSN: None     EISSN: 17591961     Source Type: Journal    
DOI: 10.1111/cen3.12107     Document Type: Review

References (57)

1. Jarius S, Wildemann B,. The history of neuromyelitis optica. J Neuroinflammation. 2013; 10: 8.
2. Jarius S, Wildemann B,. The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol. 2012; 259: 1354-7.
3. Gault F,. De la neuromyélite optique aiguë. Faculté de Médecine et de Pharmacie, 1894.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR,. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202: 473-7.
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-12.
6. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008; 70: 2197-200.
7. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006; 59: 566-9.
8. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010; 298: 158-62.
9. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012; 9: 14.
10. Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008; 255: 305-7.
11. Palace J, Leite MI, Nairne A, Vincent A,. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010; 67: 1016-7.
12. Harrer A, Tumani H, Niendorf S, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler. 2013; 19: 1209-12.
13. Jurynczyk M, Zaleski K, Selmaj K,. Natalizumab and the development of extensive brain lesions in neuromyelitis optica. J Neurol. 2013; 260: 1919-21.
14. Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology. 2012; 79: 1065-6.
15. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012; 69: 239-45.
16. Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD,. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012; 18: 108-12.
17. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG,. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66 (10): 1485-9.
18. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG,. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53 (5): 1107-14.
19. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50 (1): 121-7.
20. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58 (6): 840-6.
21. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983; 13 (3): 227-31.
22. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007; 68 (13): 1076-7.
23. Hayakawa S, Mori M, Okuta A, et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol. 2008; 196 (1-2): 181-7.
24. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008; 65 (7): 913-9.
25. Magana SM, Pittock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF,. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol. 2009; 66 (8): 964-6.
26. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009; 66 (9): 1134-8.
27. Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010; 291 (1-2): 52-6.
28. Apiwattanakul M, Asawavichienjinda T, Pulkes T, et al. Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients. J Neurol Sci. 2012; 320 (1-2): 118-20.
29. Long Y, Hu X, Peng F, et al. Neuromyelitis optica immunoglobulin g in chinese patients detected by immunofluorescence assay on a monkey brain substrate. NeuroImmunoModulation. 2012; 19 (1): 20-4.
30. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78 (9): 665-71.
31. Kim YJ, Jung SW, Kim Y, Park YJ, Han K, Oh EJ,. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: comparison of tissue-based and cell-based indirect immunofluorescence assays and ELISA. J Clin Lab Anal. 2013; 26: 184-9.
32. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F,. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol. 2007; 254 (9): 1233-7.
33. Marignier R, De Seze J, Vukusic S, et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler. 2008; 14: 440-5.
34. Chan KH, Kwan JS, Ho PW, Ho JW, Chu AC, Ramsden DB,. Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflammation. 2010; 7: 50.
35. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007; 130 (Pt 5): 1235-43.
36. Mader S, Lutterotti A, Di Pauli F, et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS ONE. 2010; 5: e10455.
37. Granieri L, Marnetto F, Valentino P, et al. Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS ONE. 2012; 7: e38896.
38. Isobe N, Yonekawa T, Matsushita T, et al. Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Mult Scler. 2012; 18: 1541-51.
39. Kalluri SR, Illes Z, Srivastava R, et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol. 2010; 67: 1201-8.
40. Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ,. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler. 2011; 12: 1527-30.
41. Kim W, Lee JE, Li XF, et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler. 2012; 5: 578-86.
42. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007; 4: e133.
43. McKeon A, Pittock SJ,. Neuromyelitis optica and the evolving spectrum of water channel autoimmunity: a new direction. Eur J Neurol. 2009; 16: 433-5.
44. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013; 81: 1197-204.
45. Rossi A, Baumgart F, van Hoek AN, Verkman AS,. Post-Golgi supramolecular assembly of aquaporin-4 in orthogonal arrays. Traffic. 2012; 13: 43-53.
46. Rash JE, Davidson KG, Yasumura T, Furman CS,. Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly. Neuroscience. 2004; 129: 915-34.
47. Furman CS, Gorelick-Feldman DA, Davidson KG, et al. Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc Natl Acad Sci USA. 2003; 100: 13609-14.
48. Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, Verkman AS,. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J Biol Chem. 2011; 286: 16516-24.
49. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008; 131 (Pt 11): 3072-80.
50. Apiwattanakul M, McKeon A, Pittock SJ, Kryzer TJ, Lennon VA,. Eliminating false-positive results in serum tests for neuromuscular autoimmunity. Muscle Nerve. 2010; 41: 702-4.
51. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M,. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012; 69: 1176-80.
52. McKeon A, Pittock SJ, Lennon VA,. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology. 2011; 76: 1108-10.
53. Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010; 7: 52.
54. Jarius S, Franciotta D, Paul F, et al. Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci. 2012; 320: 32-7.
55. Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012; 78: 1601-7.
56. Nishiyama S, Ito T, Misu T, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology. 2009; 72: 1960-1.
57. Nagaishi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry. 2011; 82: 1360-4.